18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Norman R. Relkin, Paul Szabo, Basia Adamiak, Tuna Burgut, Carmen Monthe, Richard W. Lent, Steven G Younkin, Linda Younkin, Richard Schiff, Marc E. Weksler

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.

Original languageEnglish (US)
Pages (from-to)1728-1736
Number of pages9
JournalNeurobiology of Aging
Volume30
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Intravenous Immunoglobulins
Alzheimer Disease
Therapeutics
Amyloid
Anti-Idiotypic Antibodies
Hepatitis Antibodies
Antibodies
Immunotherapy
Psychiatry
Half-Life
Cerebrospinal Fluid
Immunoglobulin G
Serum

Keywords

  • Alzheimer's disease
  • Amyloid beta peptides
  • Immunotherapy
  • Intravenous immunoglobulin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., ... Weksler, M. E. (2009). 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiology of Aging, 30(11), 1728-1736. https://doi.org/10.1016/j.neurobiolaging.2007.12.021

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. / Relkin, Norman R.; Szabo, Paul; Adamiak, Basia; Burgut, Tuna; Monthe, Carmen; Lent, Richard W.; Younkin, Steven G; Younkin, Linda; Schiff, Richard; Weksler, Marc E.

In: Neurobiology of Aging, Vol. 30, No. 11, 11.2009, p. 1728-1736.

Research output: Contribution to journalArticle

Relkin, NR, Szabo, P, Adamiak, B, Burgut, T, Monthe, C, Lent, RW, Younkin, SG, Younkin, L, Schiff, R & Weksler, ME 2009, '18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease', Neurobiology of Aging, vol. 30, no. 11, pp. 1728-1736. https://doi.org/10.1016/j.neurobiolaging.2007.12.021
Relkin, Norman R. ; Szabo, Paul ; Adamiak, Basia ; Burgut, Tuna ; Monthe, Carmen ; Lent, Richard W. ; Younkin, Steven G ; Younkin, Linda ; Schiff, Richard ; Weksler, Marc E. / 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. In: Neurobiology of Aging. 2009 ; Vol. 30, No. 11. pp. 1728-1736.
@article{001043cd0b4d40d290af8d95befdc065,
title = "18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease",
abstract = "Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.",
keywords = "Alzheimer's disease, Amyloid beta peptides, Immunotherapy, Intravenous immunoglobulin",
author = "Relkin, {Norman R.} and Paul Szabo and Basia Adamiak and Tuna Burgut and Carmen Monthe and Lent, {Richard W.} and Younkin, {Steven G} and Linda Younkin and Richard Schiff and Weksler, {Marc E.}",
year = "2009",
month = "11",
doi = "10.1016/j.neurobiolaging.2007.12.021",
language = "English (US)",
volume = "30",
pages = "1728--1736",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

AU - Relkin, Norman R.

AU - Szabo, Paul

AU - Adamiak, Basia

AU - Burgut, Tuna

AU - Monthe, Carmen

AU - Lent, Richard W.

AU - Younkin, Steven G

AU - Younkin, Linda

AU - Schiff, Richard

AU - Weksler, Marc E.

PY - 2009/11

Y1 - 2009/11

N2 - Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.

AB - Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.

KW - Alzheimer's disease

KW - Amyloid beta peptides

KW - Immunotherapy

KW - Intravenous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=70049083865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049083865&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2007.12.021

DO - 10.1016/j.neurobiolaging.2007.12.021

M3 - Article

C2 - 18294736

AN - SCOPUS:70049083865

VL - 30

SP - 1728

EP - 1736

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 11

ER -